Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer

Area of Science:

• Molecular biology
• Oncology
• Gastroenterology

Background:

• CDX2 is an intestine-specific tumor suppressor gene crucial for development and differentiation.
• CDX2 expression is often reduced in colorectal cancers, while cyclooxygenase-2 (COX-2) is frequently upregulated.
• The molecular link between CDX2 downregulation and COX-2 upregulation in colorectal cancer remains unclear.

Purpose of the Study:

• To investigate the molecular relationship between CDX2 and COX-2 in colorectal cancer.
• To determine if CDX2 affects COX-2 expression and its promoter activity.
• To elucidate the mechanism by which CDX2 might regulate COX-2.

Main Methods:

• Ectopic expression of CDX2 in colorectal cancer cells.
• Reporter assays to measure COX-2 promoter activity.
• Treatment with phorbol 12-myristate 13-acetate (PMA) to induce changes in gene expression.
• Co-immunoprecipitation to assess protein interactions between CDX2 and NF-kappaB subunits.

Main Results:

• Ectopic CDX2 expression suppressed PMA-induced COX-2 promoter activity in a dose-dependent manner.
• PMA treatment reduced endogenous CDX2 levels and increased endogenous COX-2 levels in colorectal cancer cells.
• CDX2 was found to co-immunoprecipitate with the p65 subunit of NF-kappaB and inhibit NF-kappaB promoter activity.

Conclusions:

• CDX2 directly downregulates COX-2 promoter activity, likely through interaction with NF-kappaB.
• Reduced CDX2 expression in colorectal cancer may contribute to carcinogenesis by promoting inflammatory genes like COX-2.
• These findings highlight a potential mechanism linking CDX2 loss to increased inflammation and tumor progression in the colon.